Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Oct 25, 2023

Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023

Oct 24, 2023

Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

Oct 17, 2023

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

Oct 2, 2023

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

Sep 18, 2023

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

Sep 11, 2023

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Sep 5, 2023

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

Aug 14, 2023

Cellectar Provides a Research and Development Program Summary

Jun 12, 2023

UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023